NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
Clinical Trials
10 trialsNCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT07269158 2025-12-08
A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer
Yonsei University
Phase 1/2 Not yet recruiting
NCT05967182 2025-10-24
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06178445 2025-08-19
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06923475 2025-04-11
NEODISCO
Amsterdam UMC, location VUmc
Phase 2/3 Not yet recruiting
NCT04306367 2025-02-17
Study of Pembrolizumab and Olaparib in Bile Duct Cancer
Georgetown University
Phase 2 Completed
NCT03895970 2023-03-29
Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary Tumors
Peking Union Medical College Hospital
Phase 2 Completed
NCT02982720 2022-02-16
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02757391 2020-10-30
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated